The year 2024 has been a year filled with challenges and opportunities for Zhejiang Genom Life Health Holding Group Co., Ltd. (hereinafter referred to as "GENOMBIO"). Over the past year, we have achieved remarkable results in strategic planning, technological innovation, product development, and market expansion. These accomplishments have not only driven the company’s growth but also contributed to the advancement of the life and health industry. Below are the highlights of GENOMBIO in 2024.
01 Technological Innovation and Honors
In May 2024, two subsidiaries under GENOMBIO—Zhejiang Genom CytoBio Biotechnology Co., Ltd. and Hangzhou Genom Biopharmaceutical Technology Co., Ltd.—were honored as "Zhejiang Provincial Technology-based SMEs" for their outstanding contributions in the field of cell biology.
In September 2024, GENOMBIO’s subsidiary—Genom Biopharmaceutical Technology (Anhui) Co., Ltd.—was awarded the title of "National Technology-based SME."
In December 2024, another subsidiary of GENOMBIO—Hangzhou Genom Biopharmaceutical Technology Co., Ltd.—was recognized as a "National High-Tech Enterprise." These honors are not only a testament to our scientific research strength but also a driving force that inspires us to continue forging ahead.
02 Launch of Heavyweight New Products
From June to August 2024, GENOMBIO consecutively launched three star products: Matrigel, MSC Serum-Free Medium, and Serum-Free Cell Cryopreservation Solution. Each new product embodies the company’s in-depth research in the fields of cell therapy and regenerative medicine, meeting market demand for high-quality biological products and earning high praise and trust from customers.
GENOMBIO-Organoid | Matrigel
GENOMBIO | MSC Serum-Free Medium
GENOMBIO | Serum-Free Cell Cryopreservation Solution
03 Enhanced Guarantees, Trusted Choice
In September 2024, GENOMBIO secured product liability insurance from PICC for its entire product line. This move not only demonstrates the company’s strong commitment to product quality but also provides consumers with comprehensive safety assurance, boosting market confidence. Through this insurance mechanism, we pledge to deliver premium service and support to every customer.
04 Deepening Exchanges, Collaborative Development
In September 2024, Mr. Zhang Yifei, Party Committee Secretary and Executive Vice President of Neptunus Bioengineering, and his delegation visited GENOMBIO, where both parties held in-depth discussions on future collaboration.
In November 2024, GENOMBIO and its seven wholly-owned subsidiaries participated in the 16th Cell Industry Congress (Suzhou) and the 15th China (Taizhou) International Medical Expo. These two grand events gathered leading experts and industry elites in cell biology from around the world to discuss cutting-edge topics such as cell and gene therapy, showcasing GENOMBIO’s latest achievements and technological capabilities in the biopharmaceutical field.
Additionally, in November 2024, Mr. Xu Shehua, Party Branch Secretary of the Hangzhou Bozhou Chamber of Commerce, and Secretary-General Mr. Mu Yuehua visited GENOM Health to inspect and exchange views on the company’s operations and development, further deepening mutual cooperation.
05 Advancing Information Technology
In November 2024, the official website of GENOMBIO (http://genomcell.com/) was officially upgraded and relaunched. The revamped site added new content covering scientific research services, Matrigel, organoids, and related business areas. This upgrade not only enhances user experience but also strengthens the Group’s investment in information technology, laying a solid foundation for future business expansion. The optimized website marks another step forward in the Group’s business development, external communication, and IT capabilities.
06 Social Responsibility, Boosting Local Economy
In 2024, GENOMBIO achieved significant milestones in local economic development and social responsibility. On September 21, Dr. Li Liang, Chairman and President of the Group, was invited to attend the Council Expansion Meeting of the Shanghai Anhui Bozhou Chamber of Commerce, where Dr. Li was elected as the rotating president. Through active participation in chamber activities, Dr. Li is committed to building platforms for communication and collaboration among member enterprises, promoting resource sharing and mutual development. GENOMBIO was also named the rotating president unit.
In October, GENOMBIO donated to the construction of the Anhui Lixin County Chinese Communist Party History Learning Museum through the Lixin County Charity Association. For this contribution, the company was honored as a "Cultural Glory Fund Donating Unit" by the Lixin County United Front Work Department, Lixin County Federation of Industry and Commerce (General Chamber of Commerce), and Lixin County Charity Association. This recognition highlights the company’s steadfast commitment to social responsibility.
Shortly afterward, GENOMBIO was designated as a "Bozhou City Business Environment Monitoring Point (2024)" by the Bozhou City Leading Group Office for Creating a First-Class Business Environment, reflecting the local government’s high recognition and support for the company’s work.
At the end of December 2024, a delegation from the China Animal Agriculture Association visited Genom Biopharmaceutical Technology (Anhui) Co., Ltd. to learn about the company’s practices and progress in the biopharmaceutical sector, further demonstrating the company’s dedication to social responsibility.
Under the guidance of China’s "Healthy China 2030" plan and policies promoting innovation in the biopharmaceutical industry, GENOMBIO will continue to uphold the philosophy of "Innovation-Driven, Quality First" in 2025, striving to become a leading brand in the whole-cell industry chain services. We will further expand our health services to provide more attentive and comprehensive solutions for both new and existing customers. In terms of biological reagent R&D, we will deeply optimize our product line to launch more high-quality cell culture reagents that support scientific innovation. For technical services, we will implement meticulous project management to ensure efficient operations at every stage, adding value to our customers’ research endeavors.
At the same time, GENOMBIO will actively respond to national initiatives, strengthening its presence in cutting-edge fields such as stem cell therapy and cell-based drug development, and driving the growth of the entire biopharmaceutical industry chain to contribute more to the realization of "Healthy China."
About GENOMBIO
Zhejiang Genom Life Health Holding Group Co., Ltd. is a high-tech enterprise specializing in cell therapy, gene therapy, and regenerative medicine. The company is dedicated to providing comprehensive support and services to global scientific researchers and medical institutions through technological innovation and high-quality products.